(Q43162616)

15 November 2017

Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network (English)

1 reference

15 November 2017

1 reference

12

L Boccon-Gibod

1 reference

15 November 2017

G G Malouf

1

1 reference

15 November 2017

P Camparo

2

1 reference

15 November 2017

S Oudard

3

1 reference

15 November 2017

G Schleiermacher

4

1 reference

15 November 2017

C Theodore

5

1 reference

15 November 2017

A Rustine

6

1 reference

15 November 2017

J Dutcher

7

1 reference

15 November 2017

B Billemont

8

1 reference

15 November 2017

O Rixe

9

1 reference

15 November 2017

E Bompas

10

1 reference

15 November 2017

A Guillot

11

1 reference

15 November 2017

J Couturier

13

1 reference

15 November 2017

V Molinié

14

1 reference

15 November 2017

B Escudier

15

1 reference

15 November 2017

12 February 2010

1 reference

15 November 2017

1 reference

15 November 2017

21

1 reference

15 November 2017

1834-1838

1 reference

15 November 2017

9

1 reference

Adult Xp11 translocation renal cell carcinoma diagnosed by cytogenetics and immunohistochemistry.

15 November 2017

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ029

Renal translocation carcinomas: clinicopathologic, immunohistochemical, and gene expression profiling analysis of 31 cases with a review of the literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ029

Xp11 translocation renal cell carcinoma in adults: expanded clinical, pathologic, and genetic spectrum

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ029

An aggressive course of Xp11 translocation renal cell carcinoma in a 28-year-old man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ029

Renal carcinoma-associated transcription factors TFE3 and TFEB are leukemia inhibitory factor-responsive transcription activators of E-cadherin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ029

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ029

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ029

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ029

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ029

RECIST revisited: a review of validation studies on tumour assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ029

Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ029

Response to sunitinib malate in advanced alveolar soft part sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ029

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDQ029

1 reference

15 November 2017

1 reference